Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disorders
about
Current developments in pharmacological therapeutics for chronic constipationTreatment for constipation: new and old pharmacological strategiesUse of Prucalopride for Chronic Constipation: A Systematic Review and Meta-analysis of Published Randomized, Controlled TrialsEmerging Pharmacologic Therapies for Constipation-predominant Irritable Bowel Syndrome and Chronic Constipation.Linaclotide: A new drug for the treatment of chronic constipation and irritable bowel syndrome with constipationProkinetic effects of LD02GIFRO on functional gastrointestinal disorder in rats.Serotonin signalling in the gut--functions, dysfunctions and therapeutic targets.Preliminary safety and efficacy profile of prucalopride in the treatment of systemic sclerosis (SSc)-related intestinal involvement: results from the open label cross-over PROGASS study.Prokinetics for the treatment of functional dyspepsia: Bayesian network meta-analysis.Serotonergic Mechanisms Regulating the GI Tract: Experimental Evidence and Therapeutic RelevanceNovel therapeutic agents in neurogastroenterology: advances in the past year.Constipation-predominant irritable bowel syndrome: a review of current and emerging drug therapies.Metabolic and toxicological considerations for the latest drugs used to treat irritable bowel syndrome.Effect of Prucalopride in the Treatment of Chronic Constipation in Asian and Non-Asian Women: A Pooled Analysis of 4 Randomized, Placebo-controlled Studies.Emerging drugs for the treatment of gastroparesis.The effects of camicinal, a novel motilin agonist, on gastro-esophageal function in healthy humans-a randomized placebo controlled trial.Irritable bowel syndrome: the evolution of multi-dimensional looking and multidisciplinary treatmentsSystematic review with meta-analysis: highly selective 5-HT4 agonists (prucalopride, velusetrag or naronapride) in chronic constipation.Addition of prokinetics to PPI therapy in gastroesophageal reflux disease: a meta-analysis.Rehabilitating drug-induced long-QT promoters: in-silico design of hERG-neutral cisapride analogues with retained pharmacological activity.Optimal management of constipation associated with irritable bowel syndromeProkinetics in the Management of Functional Gastrointestinal Disorders.Advancing treatment options for chronic idiopathic constipation.Electroacupuncture versus Moxibustion for Irritable Bowel Syndrome: A Randomized, Parallel-Controlled TrialVelusetrag for the treatment of chronic constipation.Chronic constipation: new diagnostic and treatment approachesEarly investigational therapeutics for gastrointestinal motility disorders: from animal studies to Phase II trials.Drug development for the irritable bowel syndrome: current challenges and future perspectivesActing on Hormone Receptors with Minimal Side Effect on Cell Proliferation: A Timely Challenge Illustrated with GLP-1R and GPEREfficacy and Safety of Prucalopride in Chronic Constipation: An Integrated Analysis of Six Randomized, Controlled Clinical Trials.Novel pharmacological therapies for management of chronic constipation.Prucalopride reduces the number of reflux episodes and improves subjective symptoms in gastroesophageal reflux disease: a case seriesPrucalopride exerts neuroprotection in human enteric neurons.Prucalopride: evaluation of the pharmacokinetics, pharmacodynamics, efficacy and safety in the treatment of chronic constipation.New treatments for IBS.Elobixibat for the treatment of constipation.Functional constipation in childhood: current pharmacotherapy and future perspectives.Diabetic gastroparesis: recent insights into pathophysiology and implications for management.Constella™(EU)-Linzess™(USA): the last milestone in the long journey of the peptide linaclotide and its implications for the future of peptide drugs.Treatment of opioid-induced constipation: focus on the peripheral μ-opioid receptor antagonist methylnaltrexone.
P2860
Q27025474-7DC64043-8541-4F98-A9B7-003E7C32BCC4Q27027346-585E8676-9EEA-45D2-B633-8873E19FD238Q33467828-ABF20278-106B-4177-9C92-2E49A1BE8E15Q33586854-A5290F39-5EF2-43DF-8051-17132C90C18EQ33695487-0161E8FE-3C28-4CD2-860B-F96832924675Q33723986-6F2E076A-C620-481A-8539-0DFBB60ED160Q33724343-2BDCD5EB-E53C-46EB-8FCF-E2C181934146Q33816342-47E7F587-4D3C-4479-A696-86221C9A46B7Q33836928-AB6256C2-E2F0-45D2-8DC8-8E711B78FF35Q33926234-0DA84A56-CAE1-4B4A-A3AB-1ADEE4D6BD4EQ33934623-8472EDCA-D939-4C99-83F0-2AE21F37CE58Q33958710-67DAD1F2-406B-42C1-A390-459B46C158B3Q34323319-3928C051-8E96-40DE-9212-22F76C89C7D8Q34377144-62A97798-290E-40BE-9631-6722D549FD84Q34412103-DBF76883-7CE7-4A3B-B465-0EA525BF80BFQ34493046-C32A7981-1148-40BE-BC72-DA94C6D0590FQ34660338-5ACC2791-7ABD-4F39-94BC-4B5C72592BACQ35059682-1B03146A-056D-4B24-B4A1-F299B384D27DQ35113619-13D76FA6-1CF7-412C-A7BD-2A40A7224C71Q35114020-60B0C4F4-96A0-4DC4-B4DB-B00E0BA73D57Q35586543-1559C448-5530-4FF2-9625-67858CA31A7AQ35834499-365F12B2-D970-48ED-A830-53B994F96353Q35858864-82B11AB7-8A54-4ECD-8380-B050D349AAF3Q35947231-68E67BF3-7357-4A4B-BEEE-AA9C5F669205Q36042950-625AB7DF-1520-4434-B77E-3461EE3A4754Q36072686-FF344137-0444-445E-B671-C34BAF4A0EAAQ36082843-5E1D1BC0-D413-44D8-AB6C-43998D6C8C9EQ36579818-E646708A-A48F-47E9-A02A-3C34C4B9CFEEQ36800401-63C6B22B-AC7B-462F-ACCA-36C921D291A6Q37092661-F5A19971-900D-4C47-B36B-72501204BAAEQ37394824-04AF5974-E923-4E5E-A8FE-1978951D98DFQ37582356-835FA4F1-289E-41E8-8A40-59B78A813A5AQ37592506-4CA0A43C-FF4E-4573-BB79-8271EDF86906Q38044067-8C41D924-3D4A-4D06-B8B5-3ECF8117998EQ38059436-0820FABB-D413-41E8-9213-42474FE42DF5Q38065210-3F49145A-8111-41DA-B4AC-BC73CAB2A974Q38065282-2E88A9BA-18EC-40E3-9150-73013B225BECQ38077822-B3DC1C20-82B3-4EE8-8B6A-D225830A07A7Q38086870-B06223AB-3646-42BA-A068-37A001E795C8Q38123753-03C17B87-71DD-48E5-9C94-F91531C2ACEA
P2860
Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disorders
description
2012 nî lūn-bûn
@nan
2012 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Systematic review: cardiovascular safety profile of 5-HT
@nl
Systematic review: cardiovascu ...... for gastrointestinal disorders
@ast
Systematic review: cardiovascu ...... for gastrointestinal disorders
@en
type
label
Systematic review: cardiovascular safety profile of 5-HT
@nl
Systematic review: cardiovascu ...... for gastrointestinal disorders
@ast
Systematic review: cardiovascu ...... for gastrointestinal disorders
@en
prefLabel
Systematic review: cardiovascular safety profile of 5-HT
@nl
Systematic review: cardiovascu ...... for gastrointestinal disorders
@ast
Systematic review: cardiovascu ...... for gastrointestinal disorders
@en
P2093
P2860
P921
P1476
Systematic review: cardiovascu ...... for gastrointestinal disorders
@en
P2093
E M M Quigley
J H De Maeyer
J J Galligan
J Schuurkes
M Camilleri
S Müller-Lissner
V Stanghellini
P2860
P304
P356
10.1111/J.1365-2036.2012.05011.X
P407
P577
2012-02-22T00:00:00Z
2012-04-01T00:00:00Z